Stocks Health care PDEX
NASDAQ · Health carePro Dex Inc (PDEX)
Pro Dex Inc brought in $79.6M of revenue over the twelve months to September 30, 2026, up 13.3% from a year earlier. Net income was $12M, a net margin of 15.1%. Operating cash flow minus capital spending left $6.8M of free cash flow in fiscal 2026. At September 30, 2026 it held $11.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Pro Dex Inc
- Net worth
- Pro Dex Inc has a market value (market cap) of $224.5M at the latest share price, and shareholders' equity of $49.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $77.5M (+16.5% year on year), with net income of $13.7M. Over the 12 months to September 30, 2026: revenue $79.6M, net income $12M.
- Cash flow
- In fiscal 2026 operations brought in $7.2M of cash; after $483K of capital spending, free cash flow was $6.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Pro Dex Inc's next report is expected around January 28, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Pro Dex Inc does
Pro Dex Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PDEX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $77.5M | $13.7M | $4.12 | $6.8M |
| 2025 | $66.6M | $9M | $2.67 | -$2.9M |
| 2024 | $53.8M | $2.1M | $0.60 | n/a |
| 2023 | $46.1M | $7.1M | $1.95 | n/a |
| 2022 | $42M | $4.6M | $1.21 | -$2.5M |
| 2021 | $38M | $6.2M | $1.57 | -$3.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PDEX ranks in Health care
Latest SEC filings
What Pro Dex Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026
- October 29, 2026
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 11% to $20.6M versus the same quarter last year; diluted EPS $0.92 versus $1.40.
- October 6, 2026
- October 6, 2026Additional proxy material DEFA14A
- October 6, 2026Proxy statement DEF 14A
- September 18, 2026Material agreement8-KPro-Dex entered into a lease amendment extending the term for its headquarters and manufacturing facility through September 30, 2030.
- September 3, 2026
- September 3, 2026Annual report 10-K · period to June 30, 2026Revenue rose 16% to $77.5M versus the prior year; diluted EPS $4.12 versus $2.67.
- August 28, 2026
What is PDEX worth? A DCF from its reported cash flow
Insider trades
What the people running Pro Dex Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.4M worth of shares in the last 90 days and bought none on the open market. Most of the selling (90%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 11, 2026 | Van Kirk Richard Lee JrChief Executive Officer, Director | Soldpre-planned (10b5-1) | 290 | $17.1K |
| September 11, 2026 | Van Kirk Richard Lee JrChief Executive Officer, Director | Soldpre-planned (10b5-1) | 475 | $28.3K |
| September 9, 2026 | Charlton AlishaChief Financial Officer | Sold | 1,500 | $91.6K |
| September 9, 2026 | Charlton AlishaChief Financial Officer | Sold | 800 | $49.4K |
| September 9, 2026 | Van Kirk Richard Lee JrChief Executive Officer, Director | Soldpre-planned (10b5-1) | 2,160 | $127.3K |
| September 9, 2026 | Van Kirk Richard Lee JrChief Executive Officer, Director | Soldpre-planned (10b5-1) | 2,691 | $161K |
| September 9, 2026 | Van Kirk Richard Lee JrChief Executive Officer, Director | Soldpre-planned (10b5-1) | 4,274 | $259.5K |
| September 9, 2026 | Van Kirk Richard Lee JrChief Executive Officer, Director | Soldpre-planned (10b5-1) | 1,157 | $71.6K |
Who owns PDEX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Swenson Nicholas John13D, may seek influence with 3 related filers | 31.88% | June 26, 2026 |
| Cabillot Raymond E13D, may seek influence with 3 related filers | 8.8% | March 27, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 67 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 153,178 | +663 |
| Vanguard Capital Management LLC | 82,283 | -29,047 |
| Dimensional Fund Advisors LP | 57,061 | +120 |
| Punch & Associates Investment Management, Inc. | 52,735 | -9,000 |
| Geode Capital Management, LLC | 49,636 | +1,289 |
| Jpmorgan Chase & Co | 32,287 | +251 |
| State Street Corp | 31,310 | -1,804 |
| Goldman Sachs Group Inc | 18,711 | +8,570 |
| Pekin Hardy Strauss, Inc. | 16,500 | new |
| Bnp Paribas Financial Markets | 15,945 | +2,711 |
| Northern Trust Corp | 15,615 | -31,076 |
| Vanguard Portfolio Management LLC | 14,332 | +1,895 |
| LPL Financial LLC | 14,297 | +1,237 |
| Jane Street Group, LLC | 13,638 | new |
| Vanguard Fiduciary Trust Co | 13,300 | +232 |
| Bank of New York Mellon Corp | 11,587 | +528 |
| Corsair Capital Management, L.P. | 10,835 | 0 |
| Bard Associates Inc | 9,799 | -767 |
| Nuveen, LLC | 9,247 | +4,250 |
| Osaic Holdings, Inc. | 9,060 | -2,514 |
Insiders
8 insiders reported holding 245,605 shares in total, about $17.3M at the last price.
| Holder | Shares |
|---|---|
| Swenson Nicholas JohnDirector, 10% owner | 97,613 |
| Van Kirk Richard Lee JrChief Executive Officer, Director | 79,228 |
| Charlton AlishaChief Financial Officer | 21,870 |
| Philp Katrina Marie KramerDirector | 19,79616,896 held indirectly |
| Domingo Angelita RebamontanDirector | 18,798 |
| Hovda DavidDirector | 4,300 |
| Farrell William James IIIDirector | 2,000 |
| Cabillot Raymond EDirector, 10% owner | 2,000 |
Questions about PDEX
What does Pro Dex Inc do?
Pro Dex Inc is a company in the Health care sector, listed on NASDAQ as PDEX. Its shares trade on NASDAQ under the ticker PDEX.
What is Pro Dex Inc's net worth?
Pro Dex Inc has a market value (market cap) of $224.5M at the latest share price, and shareholders' equity of $49.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pro Dex Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $12M on revenue of $79.6M, a net margin of 15.1%.
How much revenue does Pro Dex Inc make?
Over the twelve months to September 30, 2026 Pro Dex Inc reported revenue of $79.6M. That is 13.3% more than a year earlier.
When did Pro Dex Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the material agreement from October 30, 2026.
When is Pro Dex Inc's next earnings report?
Pro Dex Inc's next report is expected around January 28, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PDEX with
Follow PDEX
Get an email when Pro Dex Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pro Dex Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.